Q Chip receives $3M of funding; Vyteris merges with MediSync

> Q Chip, a Cardiff, Wales-based company developing sustained release injectable depot formulations, has reached the first close of $3 million of a planned $4.6 million funding round. The money will go toward scale-up of its Q-Sphera technology Q-Chip has raised about $11.5 million to date. Q Chip release

> Vyteris, a New Jersey-based drug-delivery technology company, has taken on MediSync BioServices as a wholly owned subsidiary. MediSync’s specialty is product development, clinical trial management, and data management services for the biotech industry. Vyteris release

> Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies. Report

> A Czech on progress in drug delivery. Radio Report

Drug delivery patent application of the week: Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye. Application

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.